Pfizer Inc. has finalized a significant licensing agreement with 3SBio, Inc., securing exclusive global rights, excluding China, for the development, manufacturing, and commercialization of SSGJ-707, an innovative cancer immunotherapy. This agreement includes a $1.25 billion payment to 3SBio, alongside a $100 million equity investment, and further option payments up to $150 million for exclusive rights in China. SSGJ-707, developed using 3SBio's proprietary CLF2 platform, is undergoing clinical trials in China for various cancers, including non-small cell lung cancer, with positive interim results. Pfizer plans to advance the global Phase 3 development plan, with production in North Carolina and Kansas, underscoring its commitment to pioneering cancer treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.